AstraZeneca licenses novel oral EGFR inhibitor for $1.5bn

2026-07-15T15:15:00

lung-cancer-adenocarcinoma-therapies

Source:

Agreement with Dizal Pharmaceutical gives the pharmaceutical giant access to the only approved oral targeted therapy for EGFR exon 20 insertion NSCLC in both the US and China.

AstraZeneca is licensing Zegfrovy (sunvozertinib), an innovative lung cancer drug from China’s Dizal Pharmaceutical for $1.5 billion.

This agreement enables AstraZeneca to build out its portfolio of EGFR-targeting medicines.

Dr Xiaolin Zhang, Chief Executive Officer of Dizal added: “Zegfrovy is the only oral targeted therapy for…

Already a member? Sign-in

Unlock

Driving innovation in pharma manufacturing

European Pharmaceutical Review delivers authoritative insights, cutting-edge innovations, and expert perspectives that not only inform decisions but drive measurable progress across quality, compliance, and operational excellence.

Become a member to continue reading

By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:

  • Unlimited access to industry intelligence that can make a difference to your business
  • A weekly newsletter keeping the most vital information at the front of your thinking
  • Exclusive invitations to powerful webinars and events featuring high profile experts
  • Access to deep-dive reports and analysis that reveal exciting new opportunities for business growth and transformation

Become a member